We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pre-Markets Spooked on Questions Regarding AI, Oil Prices
Read MoreHide Full Article
Key Takeaways
Nasdaq Looks to Open Down Another -750 Points
Employment Costs In-Line with Estimates
Big Oil Beats on Q3 Earnings, as Does Big Pharma
Friday, October 30th, 2026
Pre-markets are on the downslope again this morning, led by the Nasdaq shedding another -2.5% (-750 points) ahead of the open. Q3 earnings season has shown some cracks in the armor for the AI trade, particularly in the forward outlook. The Dow is -65 points at this hour, the S&P 500 is -82, and the small-cap Russell 2000 — which finished up at Thursday’s close — is down -15 points currently.
Oil prices are up again as tensions between the U.S. and Iran grow heavier. The domestic WTI spot oil price of $104 per barrel (/bbl) was the highest level in six weeks, while international Brent crude dialed back a bit to $112/bbl. If there is some good news to all of this, bond yields are also cooling a bit. The 10-year, for instance, which was around +5.35% in the first week of October, is +4.93% this morning.
Employment Costs In-Line with Estimates
This morning’s Employment Cost Index for October came in at +0.8%, in-line with estimates and down -10 basis points (bps) from the prior month. Salaries were up +0.7% while benefits advanced +0.9%. Year over year, wages grew +3.1%, benefits +3.9%. Adjusted for inflation, however, this cost index is +0.5% in October, well off the prior month’s +0.9%.
After today’s open, the ISM Chicago Business Barometer for October is expected to cool slightly to 56.0 from 58.8 reported in the previous month. These numbers are nicely above the 50-level, which determines expansion from contraction.
Q3 Earnings Morning at a Glance: Big Oil & Big Pharma
Three of the biggest integrated oil & gas supermajors reported quarterly earnings ahead of today’s opening bell. Not surprisingly, with oil prices reaching their highest levels in years based on the shutdown of the Strait of Hormuz, all three posted strong earnings numbers: ExxonMobil (XOM - Free Report) earned $4.23 per share versus expectations of $3.90, Chevron (CVX - Free Report) made $5.28 per share versus the $4.78 estimate, and BP (BP - Free Report) reached $3.26 per share against the Zacks consensus $2.66.
Big Pharma is also nicely represented this morning. AstraZeneca (AZN - Free Report) made $2.79 per share for a +7.3% earnings surprise, while AbbVie (ABBV - Free Report) posted a +2.14% earnings surprise to $3.82 per share. Regeneron (REGN - Free Report) , while not (yet) considered a Big Pharma stock, blew the doors off expectations this morning: earnings of $20.07 per share beat expectations by +24.8%.
View the Zacks #1 Rank List
Image: Bigstock
Pre-Markets Spooked on Questions Regarding AI, Oil Prices
Key Takeaways
Friday, October 30th, 2026
Pre-markets are on the downslope again this morning, led by the Nasdaq shedding another -2.5% (-750 points) ahead of the open. Q3 earnings season has shown some cracks in the armor for the AI trade, particularly in the forward outlook. The Dow is -65 points at this hour, the S&P 500 is -82, and the small-cap Russell 2000 — which finished up at Thursday’s close — is down -15 points currently.
Oil prices are up again as tensions between the U.S. and Iran grow heavier. The domestic WTI spot oil price of $104 per barrel (/bbl) was the highest level in six weeks, while international Brent crude dialed back a bit to $112/bbl. If there is some good news to all of this, bond yields are also cooling a bit. The 10-year, for instance, which was around +5.35% in the first week of October, is +4.93% this morning.
Employment Costs In-Line with Estimates
This morning’s Employment Cost Index for October came in at +0.8%, in-line with estimates and down -10 basis points (bps) from the prior month. Salaries were up +0.7% while benefits advanced +0.9%. Year over year, wages grew +3.1%, benefits +3.9%. Adjusted for inflation, however, this cost index is +0.5% in October, well off the prior month’s +0.9%.
After today’s open, the ISM Chicago Business Barometer for October is expected to cool slightly to 56.0 from 58.8 reported in the previous month. These numbers are nicely above the 50-level, which determines expansion from contraction.
Q3 Earnings Morning at a Glance: Big Oil & Big Pharma
Three of the biggest integrated oil & gas supermajors reported quarterly earnings ahead of today’s opening bell. Not surprisingly, with oil prices reaching their highest levels in years based on the shutdown of the Strait of Hormuz, all three posted strong earnings numbers: ExxonMobil (XOM - Free Report) earned $4.23 per share versus expectations of $3.90, Chevron (CVX - Free Report) made $5.28 per share versus the $4.78 estimate, and BP (BP - Free Report) reached $3.26 per share against the Zacks consensus $2.66.
Big Pharma is also nicely represented this morning. AstraZeneca (AZN - Free Report) made $2.79 per share for a +7.3% earnings surprise, while AbbVie (ABBV - Free Report) posted a +2.14% earnings surprise to $3.82 per share. Regeneron (REGN - Free Report) , while not (yet) considered a Big Pharma stock, blew the doors off expectations this morning: earnings of $20.07 per share beat expectations by +24.8%.
Questions or comments about this article and/or author? Click here>>